Conclusions
The present study shows that RDV remained an effective treatment of
COVID-19 during Delta and Omicron SARS-CoV-2 waves. Under the dominance
of both viral lineages, the mortality of hospitalized patients treated
with RDV was significantly lower than in those who did not receive any
antiviral treatment, despite the fact that these groups did not differ
in demographic and clinical characteristics. Despite the milder course
of infections caused by the Omicron variant, RDV continues to be an
important element of COVID-19 therapy.